Vivo Capital’s enGene Therapeutics Warrants ENGNW Stock Holding History

Vivo Capital’s Portfolio ENGNW Stock Details ENGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-285,046	Closed	-$844K	–	51
2025 Q4	$844K	Buy	+285,046	New	+$651K	0.05%	45

Other funds holding ENGNW

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

Vivo Capital's ENGNW Position: Q1 2026 in Review

Vivo Capital sold out of enGene Therapeutics Warrants (ENGNW) in Q1 2026, closing a stake of 285,046 shares — an estimated $844K sold.

Vivo Capital first reported a position in ENGNW in Q4 2025 and held it in 1 quarter. The position peaked at $844K in Q4 2025. 11 funds tracked by Wall St. Rank hold ENGNW as of Q1 2026.

Vivo Capital reported no remaining enGene Therapeutics Warrants position as of Q1 2026 after selling out during the quarter.
Vivo Capital sold 285,046 enGene Therapeutics Warrants shares in Q1 2026, an estimated $844K.
Vivo Capital first reported a position in enGene Therapeutics Warrants in Q4 2025 and held it in 1 quarter.
Vivo Capital's enGene Therapeutics Warrants position peaked at $844K in Q4 2025.
11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q1 2026.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.